Inoviq Ltd (IIQ) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Inoviq Ltd (IIQ) has a cash flow conversion efficiency ratio of -0.098x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$-2.18 Million ≈ $-1.54 Million USD) by net assets (AU$22.26 Million ≈ $15.75 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see IIQ stock market capitalisation for the company's overall valuation and market capitalisation.
Inoviq Ltd - Cash Flow Conversion Efficiency Trend (1991–2025)
This chart illustrates how Inoviq Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Inoviq Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Inoviq Ltd ranked by their cash flow conversion efficiency. See Inoviq Ltd cash flow to debt ratio to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
OptiCept Technologies AB
ST:OPTI
|
-0.050x |
|
Konsolidator AS
CO:KONSOL
|
0.165x |
|
Scibase AB
ST:SCIB
|
-0.457x |
|
Samjin LND Co. Ltd
KQ:054090
|
0.065x |
|
Trust Stamp Inc
NASDAQ:IDAI
|
-0.464x |
|
Despec Bilgisayar Pazarlama ve Ticaret AS
IS:DESPC
|
-1.667x |
|
Polylite Taiwan Co Ltd
TWO:1813
|
0.109x |
|
Pergamon Status Dis Ticaret AS
IS:PSDTC
|
-0.002x |
Annual Cash Flow Conversion Efficiency for Inoviq Ltd (1991–2025)
The table below shows the annual cash flow conversion efficiency of Inoviq Ltd from 1991 to 2025. View Inoviq Ltd (IIQ) stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | AU$16.71 Million ≈ $11.83 Million |
AU$-4.66 Million ≈ $-3.30 Million |
-0.279x | -28.97% |
| 2024-06-30 | AU$19.99 Million ≈ $14.14 Million |
AU$-4.32 Million ≈ $-3.06 Million |
-0.216x | +39.60% |
| 2023-06-30 | AU$19.62 Million ≈ $13.88 Million |
AU$-7.02 Million ≈ $-4.97 Million |
-0.358x | -67.16% |
| 2022-06-30 | AU$28.29 Million ≈ $20.02 Million |
AU$-6.06 Million ≈ $-4.29 Million |
-0.214x | -18.33% |
| 2021-06-30 | AU$29.06 Million ≈ $20.56 Million |
AU$-5.26 Million ≈ $-3.72 Million |
-0.181x | +53.79% |
| 2020-06-30 | AU$6.48 Million ≈ $4.58 Million |
AU$-2.54 Million ≈ $-1.79 Million |
-0.392x | -77.94% |
| 2019-06-30 | AU$7.13 Million ≈ $5.05 Million |
AU$-1.57 Million ≈ $-1.11 Million |
-0.220x | +87.34% |
| 2018-06-30 | AU$1.13 Million ≈ $799.89K |
AU$-1.97 Million ≈ $-1.39 Million |
-1.738x | +81.15% |
| 2017-06-30 | AU$257.94K ≈ $182.51K |
AU$-2.38 Million ≈ $-1.68 Million |
-9.221x | -33350.54% |
| 2016-06-30 | AU$2.83 Million ≈ $2.01 Million |
AU$-78.12K ≈ $-55.27K |
-0.028x | +61.75% |
| 2015-06-30 | AU$1.76 Million ≈ $1.24 Million |
AU$-126.65K ≈ $-89.62K |
-0.072x | -164.40% |
| 2014-06-30 | AU$888.13K ≈ $628.41K |
AU$99.38K ≈ $70.31K |
0.112x | +142.47% |
| 2013-06-30 | AU$2.92 Million ≈ $2.06 Million |
AU$-768.54K ≈ $-543.79K |
-0.263x | -465.92% |
| 2012-06-30 | AU$15.11 Million ≈ $10.69 Million |
AU$-703.24K ≈ $-497.59K |
-0.047x | +19.70% |
| 2011-06-30 | AU$26.60 Million ≈ $18.82 Million |
AU$-1.54 Million ≈ $-1.09 Million |
-0.058x | -42.54% |
| 2010-06-30 | AU$18.89 Million ≈ $13.37 Million |
AU$-768.35K ≈ $-543.66K |
-0.041x | +4.20% |
| 2009-06-30 | AU$19.03 Million ≈ $13.46 Million |
AU$-807.86K ≈ $-571.61K |
-0.042x | +65.11% |
| 2008-06-30 | AU$5.67 Million ≈ $4.01 Million |
AU$-689.60K ≈ $-487.93K |
-0.122x | +93.15% |
| 2007-06-30 | AU$2.04 Million ≈ $1.45 Million |
AU$-3.63 Million ≈ $-2.57 Million |
-1.777x | -264.88% |
| 2006-06-30 | AU$11.04 Million ≈ $7.81 Million |
AU$-5.38 Million ≈ $-3.80 Million |
-0.487x | -75.52% |
| 2005-06-30 | AU$16.88 Million ≈ $11.95 Million |
AU$-4.68 Million ≈ $-3.31 Million |
-0.277x | +19.00% |
| 2004-06-30 | AU$2.78 Million ≈ $1.97 Million |
AU$-952.64K ≈ $-674.05K |
-0.342x | +39.62% |
| 2003-06-30 | AU$2.48 Million ≈ $1.76 Million |
AU$-1.41 Million ≈ $-996.59K |
-0.567x | -127.34% |
| 2002-06-30 | AU$2.33 Million ≈ $1.65 Million |
AU$-580.86K ≈ $-411.00K |
-0.249x | -177.20% |
| 1999-06-30 | AU$9.09 Million ≈ $6.43 Million |
AU$-818.36K ≈ $-579.04K |
-0.090x | +0.39% |
| 1997-06-30 | AU$10.44 Million ≈ $7.39 Million |
AU$-943.60K ≈ $-667.65K |
-0.090x | -57.33% |
| 1996-06-30 | AU$10.31 Million ≈ $7.29 Million |
AU$-591.98K ≈ $-418.86K |
-0.057x | +6.84% |
| 1995-06-30 | AU$9.89 Million ≈ $7.00 Million |
AU$-610.00K ≈ $-431.61K |
-0.062x | +60.69% |
| 1994-06-30 | AU$9.72 Million ≈ $6.88 Million |
AU$-1.52 Million ≈ $-1.08 Million |
-0.157x | +82.55% |
| 1993-06-30 | AU$1.61 Million ≈ $1.14 Million |
AU$-1.45 Million ≈ $-1.02 Million |
-0.899x | +62.96% |
| 1992-06-30 | AU$286.00K ≈ $202.36K |
AU$-694.00K ≈ $-491.05K |
-2.427x | -128.19% |
| 1991-06-30 | AU$-23.00K ≈ $-16.27K |
AU$-198.00K ≈ $-140.10K |
8.609x | -- |
About Inoviq Ltd
INOVIQ Ltd develops and commercializes diagnostic and exosome-based products to enhance the diagnosis and treatment of cancer and other diseases in Australia and the United States. It offers hTERT ICC test, an immunocytochemistry test used as an adjunct to urine cytology testing for bladder cancer; and EXO-NET, an EV isolation tool for biomarker discovery and diagnostic development. It offers non… Read more